Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07681089
PHASE2

A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

Sponsor: Kiminori Kimura, MD

View on ClinicalTrials.gov

Summary

This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.

Official title: A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia

Key Details

Gender

MALE

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

4

Start Date

2026-09-01

Completion Date

2028-03-31

Last Updated

2026-08-05

Healthy Volunteers

No

Conditions

Interventions

DRUG

Foscenvivint

Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks

Locations (3)

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

National Hospital Organization Osaka National Hospital

Osaka, Osaka, Japan

Tokyo Metropolitan Komagome Hospital

Bunkyo-Ku, Tokyo, Japan